N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2018
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2018'; N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) pipeline Target constitutes close to 7 molecules.
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) encoded by the FPR2 gene and is activated to regulate cell function by binding to a wide variety of ligands like N-Formylmethionine-containing oligopeptides such as N-Formyl methionine-leucyl-phenylalanine (FMLP), polyunsaturated fatty acid metabolite of arachidonic acid, lipoxin A4 (LXA4). FPR2 mediates responses to a wide range of polypeptides and proteins which may serve to promote inflammation.
The report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2018' outlays comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Unknown stages are 1, 5 and 1 respectively.
Report covers products from therapy areas Cardiovascular, Immunology, Central Nervous System, Central Nervous System, Infectious Disease, Metabolic Disorders, Oncology and Ophthalmology which include indications Inflammation, Allergies, Alzheimer's Disease, Atherosclerosis, Autoimmune Disorders, Bacterial Infections, Congestive Heart Failure (Heart Failure), Fungal Infections, Ischemia Reperfusion Injury, Ischemic Stroke, Keratoconjunctivitis Sicca (Dry Eye), Metastatic Cancer, Myocardial Ischemia and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2018'; N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) pipeline Target constitutes close to 7 molecules.
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) encoded by the FPR2 gene and is activated to regulate cell function by binding to a wide variety of ligands like N-Formylmethionine-containing oligopeptides such as N-Formyl methionine-leucyl-phenylalanine (FMLP), polyunsaturated fatty acid metabolite of arachidonic acid, lipoxin A4 (LXA4). FPR2 mediates responses to a wide range of polypeptides and proteins which may serve to promote inflammation.
The report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2018' outlays comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Unknown stages are 1, 5 and 1 respectively.
Report covers products from therapy areas Cardiovascular, Immunology, Central Nervous System, Central Nervous System, Infectious Disease, Metabolic Disorders, Oncology and Ophthalmology which include indications Inflammation, Allergies, Alzheimer's Disease, Atherosclerosis, Autoimmune Disorders, Bacterial Infections, Congestive Heart Failure (Heart Failure), Fungal Infections, Ischemia Reperfusion Injury, Ischemic Stroke, Keratoconjunctivitis Sicca (Dry Eye), Metastatic Cancer, Myocardial Ischemia and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
- The report reviews N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Overview
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Companies Involved in Therapeutics Development
Allergan Plc
Bristol-Myers Squibb Co
CohBar Inc
NovaCell Technology Inc
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Drug Profiles
Drugs to Agonize FPR2 for Dry Eye - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCP-70X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Target FPR2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize FPR-2 for Heart Failure and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize FPR1 and FPR2 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Dormant Products
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Overview
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Companies Involved in Therapeutics Development
Allergan Plc
Bristol-Myers Squibb Co
CohBar Inc
NovaCell Technology Inc
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Drug Profiles
Drugs to Agonize FPR2 for Dry Eye - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCP-70X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Target FPR2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize FPR-2 for Heart Failure and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize FPR1 and FPR2 for Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Dormant Products
N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Allergan Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CohBar Inc, H2 2018
Pipeline by NovaCell Technology Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Allergan Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CohBar Inc, H2 2018
Pipeline by NovaCell Technology Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018 7
Number of Products under Development by Therapy Areas, H2 2018 8
Number of Products under Development by Top 10 Indications, H2 2018 9
Number of Products by Stage and Mechanism of Actions, H2 2018 12
Number of Products by Molecule Types, H2 2018 13
Number of Products by Stage and Molecule Types, H2 2018 13
COMPANIES MENTIONED
Allergan Plc
Bristol-Myers Squibb Co
CohBar Inc
NovaCell Technology Inc
Number of Products under Development by Stage of Development, H2 2018 7
Number of Products under Development by Therapy Areas, H2 2018 8
Number of Products under Development by Top 10 Indications, H2 2018 9
Number of Products by Stage and Mechanism of Actions, H2 2018 12
Number of Products by Molecule Types, H2 2018 13
Number of Products by Stage and Molecule Types, H2 2018 13
COMPANIES MENTIONED
Allergan Plc
Bristol-Myers Squibb Co
CohBar Inc
NovaCell Technology Inc
